Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes.
Wang B, Chandrasekera PC, Pippin JJ. · 2014
Read Leptin- and leptin receptor-deficient rodent models: relevance for human type 2 diabetes. by Wang B, Chandrasekera PC, Pippin JJ. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4082168.txt.
Introduction
Bingxuan Wang, Charukeshi Chandrasekera P., and John J. Pippin questioned how well leptin-deficient rodents model human type 2 diabetes. Their review appeared in Current Diabetes Reviews in 2014. Mice and rats lacking leptin or its receptor are among the most used animals in obesity and diabetes research.
These animals do grow obese from overeating and develop diabetes-like features. Yet their illness stems from a single inherited mutation, while human type 2 diabetes rarely involves leptin deficiency. Decades of work have uncovered many species differences that researchers keep overlooking. Comparing genes, obesity, blood sugar, and insulin across the models, the authors warn that findings from these animals often fail to translate to human disease, despite their popularity.
Catalog record
| CREATOR | Wang B, Chandrasekera PC, Pippin JJ. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes By Bingxuan Wang, Charukeshi Chandrasekera P., John J. Pippin Published in: Current Diabetes Reviews DOI: 10.2174/1573399810666140508121012 ABSTRACT Among the most widely used animal models in obesity-induced type 2 diabetes mellitus (T2DM) research are the congenital leptin- and leptin receptor-deficient rodent models. These include the leptin-deficient ob/ob mice and the leptin receptor-deficient db/db mice, Zucker fatty rats, Zucker diabetic fatty rats, SHR/N-cp rats, and JCR:LA-cp rats. After decades of mechanistic and therapeutic research schemes with these animal models, many species differences have been uncovered, but researchers continue to overlook these differences, leading to untranslatable research. The purpose of this review is to analyze and comprehensively recapitulate the most common leptin/leptin receptor-based animal models with respect to their relevance and translatability to human T2DM. Our analysis revealed that, although these rodents develop obesity due to hyperphagia caused by abnormal leptin/leptin receptor signaling with the subsequent appearance of T2DM-like manifestations, these are in fact secondary to genetic mutations that do not reflect disease etiology in humans, for whom leptin or leptin receptor deficiency is not an important contributor to T2DM. A detailed comparison of the roles of genetic susceptibility, obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and diabetic complications as well as leptin expression, signaling, and other factors that confound translation are presented here. There are substantial differences between these animal models and human T2DM that limit reliable, reproducible, and translatable insight into human T2DM. Therefore, it is imperative that researchers recognize and acknowledge the limitations of the leptin/leptin receptor-based rodent models and invest in research methods that would be directly and reliably applicable to humans in order to advance T2DM management. INTRODUCTION Type 2 diabetes mellitus (T2DM), or non-insulin-dependent diabetes mellitus, is a disease of chronic hyperglycemia that leads to severe and sometimes fatal complications. Over 26 million Americans currently have diabetes and an additional 79 million are considered pre-diabetic; 90-95% of diagnosed cases of diabetes are T2DM. In addition to costing hundreds of billions of dollars annually, T2DM is one of the leading causes of death, the leading cause of kidney failure, and a major cause of heart disease in the United States [1, 2]. Globally, the incidence of T2DM is increasing rapidly, and the World Health Organization predicts that by 2030 the prevalence of T2DM will double to 350 million worldwide [3]. As a result, the needs for means to prevent, diagnose, and treat T2DM and its complications are ever-increasing. Over the past several decades, considerable resources have been devoted to T2DM research using animal models, and the merits and limitations of various animal models have been reviewed elsewhere [4-12]. The species commonly used include cats, dogs, nonhuman primates, and especially rodents. Depending on the method(s) used to induce diabetes, these animal models can be broadly classified into spontaneous/congenital, diet-induced, chemical-induced, surgical, and transgenic diabetic models [12]. Among the most frequently used are the spontaneously diabetic rodent models deficient in leptin or leptin receptors. These models include leptin deficient ob/ob mouse, leptin receptor deficient db/db mouse, Zucker fatty rat, Zucker diabetic fatty (ZDF) rat, spontaneously hypertensive/NIH corpulent (SHR/N-cp) rat, and JCR:LA-cp rat (note that this is not a comprehensive list of all leptin or leptin receptor deficient animals since not all such models are widely used for T2DM research). Due to single-gene mutations that lead to the lack of action by the satiety factor leptin or its cognate receptor, these rodents spontaneously develop severe hyperphagia leading to obesity and manifest some T2DM-like characteristics. Of these models, the ob/ob mouse, db/db mouse, Zucker fatty rat, and ZDF rat represent some of the earliest animal models developed and remain among the most widely used models for T2DM research today generating over 4000 publications on PubMed over the last decade alone. Other corpulent (designated cp) rat models emerged later and are mainly used to study diabetic cardiovascular complications. Despite the extensive use of these rodent models, many mechanistic details of human T2DM remain poorly understood and treatment options for humans are limited and largely unsatisfactory. The purpose of this review is to analyze the experimental evidence and evaluate the relevance of leptin and leptin receptor-deficient rodent models for human T2DM. T2DM IN HUMANS The natural history of T2DM in humans leads from insulin resistance to compensatory hyperinsulinemia, pancreatic β-cell dysfunction, impaired glucose tolerance, and finally T2DM characterized by overt hyperglycemia [13]. The development of T2DM is typically slow in humans, and individuals may be asymptomatic for many years. Diverse factors contribute to insulin resistance and β-cell dysfunction, and therefore human T2DM is termed “multifactorial,” in contrast to monogenic animal models of T2DM. Both genetic and acquired factors influence T2DM susceptibility in humans. Human T2DM is associated with a number of risk factors which include obesity, advancing age, genetic predisposition (family history of diabetes and ethnic background), previous history of gestational diabetes, suboptimal intrauterine environment, low birth weight, and lifestyle factors such as consumption of high caloric diets, stress, and physical inactivity [14]. T2DM-induced complications can be categorized into macrovascular and microvascular conditions and account for the vast majority of T2DM-related morbidity and mortality [15]. The importance of genetic predisposition to T2DM has been demonstrated in twin studies [16]. Several approaches have been used for the discovery of candidate genes: linkage analysis, candidate gene association studies, and genome-wide association studies [17]. To date, polymorphisms of more than three dozen genes have been reported to be linked to T2DM, but leptin and leptin receptor genes are not among them [14, 17-19]. Moreover, since T2DM is a multifactorial disease and multiple genes are involved, each sequence variation of one gene may contribute minimally or not at all to increased T2DM susceptibility. Thus, it is crucial to evaluate various aspects of the leptin- and leptin receptor-based animal models in light of their ability to appropriately mimic aspects of T2DM in order to ensure humans can benefit from such research findings. LEPTIN/LEPTIN RECEPTOR-DEFICIENT RODENT MODELS IN RESEARCH AND DRUG DEVELOPMENT In basic research, ob/ob mice, db/db mice, Zucker fatty rats and ZDF rats have been extensively used to study the pathogenesis of T2DM, obesity, leptin signaling, and the interactions among the three. All these animal models are obese and insulin resistant with dyslipidemia and virtually all mechanistic aspects of T2DM have been examined in these animals. In drug discovery and testing, the db/db mouse is the most popular animal model used by pharmaceutical companies to test glucose lowering agents, insulin sensitizers, insulin secretagogues, and anti-obesity agents, although ob/ob mice, Zucker fatty rats and ZDF rats are also widely used [20]. The corpulent rats are less used, possibly due to their late emergence. A major advantage of spontaneous/congenital diabetic animal models is that researchers do not need to use time-consuming feeding schemes or invasive procedures that risk side effects to induce the diabetic symptoms. However, when the diabetic manifestations in some of these models do not develop in females (as detailed later in the text) or are not as apparent as desired, dietary manipulations as well as transgenic efforts have been combined to “improve” the models. Taken together, these models have been widely used for various purposes, and the following sections will address in detail the molecular basis and